Deferoxamine is an iron chelating agent used in the treatment of iron overload, acute iron toxicity and in the management of sickle cell disease.

**General description**

<table>
<thead>
<tr>
<th>INN</th>
<th>Deferoxamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>V03AC01</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1979 (TRS 641) for *Harmful effects of drugs, medicaments or biological substances, not elsewhere classified*  
Added in 2011 (TRS 965) for *Other specified sickle cell disorders or other haemoglobinopathies* |
| Wikipedia    | Deferoxamine |
| DrugBank     | Deferoxamine |

**Recommendations**

**Section**  
Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

**Indications**

- *Harmful effects of drugs, medicaments or biological substances, not elsewhere classified*

**Section**  
Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

**Indications**

- *Other specified sickle cell disorders or other haemoglobinopathies*